An intermediate report from a currently ongoing Phase1b/2a clinical trial for ACI-35.030 in people with early AD (NCT04445831) pointed to no safety problems and good immunogenicity with generation of anti phospho-tau antibodies. This evidence concerns the gene MAPT and Alzheimer disease.